Read Larry Connors' blog – Short Term Trading Strategies
Click here to view video:
http://investor.shareholder.com/ceosignature/webcast.cfm?mediaid=32977&k=AFC16803E00D3733E8682A801BE88B9C
Steven R. Deitcher, MD, was appointed President and Chief Executive Officer and a member of the Board of Directors for Hana Biosciences in August 2007. Dr. Deitcher originally joined Hana as Executive Vice President of Development and Chief Medical Officer in May 2007. From 2004 until he joined Hana, Dr. Deitcher served as Vice President, Chief Medical Scientist at Nuvelo where he was responsible for clinical development and medical affairs. Dr. Deitcher has more than 15 years of experience as a practicing physician in hematology, medical oncology and vascular medicine. Dr. Deitcher was formerly the head of the section of hematology and coagulation medicine in the department of hematology/oncology and director of research in the department of vascular medicine at The Cleveland Clinic Foundation. While at The Cleveland Clinic, Dr. Deitcher was hematology medical director for the Network for Oncology Communication and Research. Prior to that, he spent four years at The University of Tennessee in positions including associate chairman, department of medicine; director, combined pediatric and adult thrombosis clinic; and director, special coagulation laboratory. Dr. Deitcher earned his B.S. and M.D. in the Honors Program in Medical Education at Northwestern University Medical School. He completed his residency in internal medicine at Barnes Hospital and completed his fellowship training in hematology and medical oncology at New England Medical Center and Tufts University School of Medicine. Dr. Deitcher is a member of several medical societies, including The American Society of Hematology, American Society of Clinical Oncology and the International Society on Thrombosis and Hemostasis, and is a fellow of the Society for Vascular Medicine and Biology. He has published more than 185 journal papers, abstracts and book chapters and has made more than 35 scientific conference presentations. He was the founding editor-in-chief of the journal Current Hematology Reports.
About Hana Biosciences, Inc.
Hana Biosciences, Inc. (Nasdaq:HNAB) is a South San Francisco, CA-based biopharmaceutical company focused on acquiring, developing, and commercializing innovative products to strengthen the foundation of cancer care. The company is committed to creating value by building a best-in-class team, accelerating the development of lead product candidates, expanding its pipeline by being the alliance partner of choice, and nurturing a unique company culture.
For more information about NASDAQ CEO Signature Series interviews, call 978/461-3141.
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: NASDAQ CEO Signature Series; Hana Biosciences, Inc.
The NASDAQ CEO Signature Series logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4839
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
15260 Ventura Blvd., Ste. 2200
Sherman Oaks, CA 91403
© Copyright 2009 The Connors Group, Inc.
